Home > News > Genetic risk lab test utilises nanotechnology
August 25th, 2005
Genetic risk lab test utilises nanotechnology
Abstract:
The Optonanogen project, with support from the EU, aims to develop a system, which detect mutations of the BRCA1 gene responsible for between 2.5 and 5 per cent of the incidences of breast cancer in women. The final device will be roughly the size of a human hand, allowing it to be used in doctors' surgeries to determine the genetic predisposition of a patient to certain diseases in a matter of minutes.
Source:
labtechnologist.com
Related Links |
Related News Press |
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Sensors
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Groundbreaking precision in single-molecule optoelectronics August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||